Article info

Download PDFPDF

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

Authors

  1. Correspondence to Dr Sophie Glatt, Global Exploratory Development, UCB Pharma, Slough SL1 3WE, UK; Sophie.Glatt{at}ucb.com
View Full Text

Citation

Glatt S, Taylor PC, McInnes IB, et al
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

Publication history

  • Received December 18, 2018
  • Revised April 17, 2019
  • Accepted April 23, 2019
  • First published June 8, 2019.
Online issue publication 
July 11, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.